Interbody Systems: Post Market Clinical Follow-up Study

Launched by K2M, INC. · Jun 1, 2021

Keywords

ClinConnect Summary

This clinical trial is looking at patients with degenerative disc disease who will be undergoing spinal fusion surgery using specific Stryker Interbody Systems. The main goal of the study is to see if patients experience significant improvement in their neck or back pain after surgery, measured at 12 and 24 months post-operation. Researchers want to find out if these systems help improve quality of life and whether the benefits last over time.

To participate in the trial, individuals must be aged 18 or older and scheduled for spinal fusion surgery with the Stryker devices. They should have had prior non-surgical treatments for at least six months for lumbar issues or six weeks for cervical problems. Participants will need to agree to follow study procedures and provide informed consent. Those with certain medical conditions or risks, such as infections, severe osteoporosis, or specific neurological disorders, may not be eligible. Throughout the study, participants can expect regular follow-ups to monitor their progress and outcomes.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Must be planned to undergo spinal fusion surgery utilizing Stryker Interbody Systems for on label indications, which are listed below as inclusion criteria.
• • 2. Diagnosed with degenerative disc disease (DDD).
• Please note for Lumbar devices:
• • Can also be diagnosed with up to Grade 1 Spondylolisthesis and/or Degenerative Scoliosis. (Chesapeake is not indicated for degenerative scoliosis)
• • Cascadia/Mojave/ Sahara/ Monterey AL can also be diagnosed with up to Grade 1 Retrolisthesis.
• • Outside of USA, Tritanium is indicated for use in patients with diagnosis of Degenerative Spine Disorders, Spine Revision, Discal and Vertebral Instability; and there is no restriction to Spondylolisthesis Grade.
• • 3. Willingness and ability to comply with the requirements of the protocol including follow up requirements.
• • 4. Willing and able to sign a study specific informed consent form.
• 5. Skeletally mature (age at least 18 years) and:
• • 1. Have had six months of lumbar non operative therapy.
• • 2. Have had six weeks of cervical non operative treatment.
• 6. Will undergo interbody fusion at one or two contiguous levels (Chesapeake Cervical Ti is only indicated for use at one level) at:
• • 1. L2 L5 for Cascadia lateral hyperlordotic (\>22°l).
• • 2. L2 S1 for all other lumbar interbody systems.
• • 3. C2 T1 for cervical interbody systems.
• • 7. Self reports Oswestry Disability Index (ODI) score 30% (raw score of 15/50) for lumbar patients and Neck Disability Index (NDI) score 30% (raw score of 15/50) for cervical patients at pre operative visit.
• Exclusion Criteria:
• • 1. Any condition where the implants interfere with anatomical structures or precludes the benefit of spinal surgery.
• • 2. For the Tritanium and Monterey AL systems: Any neuromuscular deficit which places an unsafe load on the device during the healing period.
• • 3. For the Cascadia, Chesapeake, Mojave and Sahara systems: Metabolic disorders of calcified tissues.
• • 4. Biological factors such as smoking or using nonsteroidal anti inflammatory agents/ anticoagulants.
• • 5. Immunosuppressive disorders.
• • 6. Grossly distorted anatomy. N/A for Tritanium TL, Tritanium Cervical and Monterey AL
• • 7. Inadequate tissue coverage or open wounds.
• • 8. Infection at index level(s) at the time of surgery.
• • 9. Patients with known sensitivity to materials in the device.
• • 10. Has a neuromuscular disorder or mental condition (including general neurological conditions, mental illness, senility, and drug/alcohol abuse) which would create an unacceptable risk of fixation failure or complications in postoperative care or willingness to restrict activities or follow medical advice.
• • 11. Obesity.
• • 12. Other medical or surgical condition which would preclude the potential benefit of spinal implant surgery, such as the presence of tumors, congenital abnormalities, elevation of sedimentation rate unexplained by other diseases, elevation of white blood cell count (WBC) or marked left shift in the WBC differential count.
• • 13. For the Tritanium and Monterey AL systems: Any abnormality which affects the normal process of bone remodeling including, but not limited to severe osteoporosis involving the spine, bone absorption, osteopenia, primary or metastatic tumors involving the spine or certain metabolic disorders affecting osteogenesis.
• • Please note for Tritanium cervical this also includes rapid joint disease, bone absorption, osteopenia, osteomalacia, and/or osteoporosis.
• • 14. For the Tritanium, Monterey AL, Chesapeake and Sahara systems: Prior fusion at the level to be treated (as indicated in the IFU).
• • 15. Pregnancy, or if the patient intends to become pregnant during the course of the study.
• • 16. Incarcerated at the time of study enrollment.
• • 17. Current participation in an investigational study that may impact study outcomes.
• • 18. Involved in current or pending litigation regarding a spine surgery.
• • 19. Receiving worker's compensation.